As silicon-based photolithography reaches its feasible limits resulting in leaking electricity and rising manufacturing costs, manufacturers are searching for a new approach to make semiconductors. To make smaller circuits more quickly and less expensively, Intel and IBM are seeking to reduce the size of the smallest component from 32 nm to 7 nm using carbon […]
The National Human Genome Research Institute (NHGRI) has announced a four-year, $416 million plan to expand its Genome Sequencing Program. An initial amount of $86 million annually will support basic research, new initiatives and technological improvements at three large genome sequencing centers. For the first year, fiscal 2012, the Broad Institute, Washington University and Baylor […]
More often than not, scientists are unable to reproduce medical research results. The lack of reproducibility is likely due to more complicated experiments as laboratory methods evolve, the use of different equipment and materials by different studies, the high number of variables present in a study, authors not presenting all information to other researchers, and […]
Among the issues raised in a November report by the US Department of Energy’s (DOE) Office of Inspector General reviewing management challenges for fiscal 2012 was the cost of DOE labs. The report recommends the creation of an independent commission to analyze the DOE’s R&D lab complex. The DOE spends $10.4 billion annually to run […]
The World Steel Association’s October 2011 short-range outlook predicts that worldwide apparent steel use, which it defines as steel deliveries from domestic producers and importers and not from inventories, will increase 6.5% to 1,398 million metric tons (mmt) in 2011, down from 15.1% growth last year. Global steel demand should grow 5.4% in 2012. China […]
From 2010 to 2011, 10 of the 12 drug firms that spend the most on R&D had declining Internal Rates of Return (IRR), which is the return firms expect on investment. The firms were Pfizer, Sanofi, Takeda, Roche, AstraZeneca, Merck, Novartis, GlaxoSmithKline, Amgen, Eli Lilly, Johnson & Johnson and Bristol-Myers Squibb. The collective IRR for […]
For the first half of 2011, corporate venture funds comprised 12% of overall venture capital investment, up from 5.3% in 2010, according to PricewaterhouseCoopers and the National Venture Capital Association. Corporate venture funds were responsible for 25% of early-stage biotech financing in the first half of this year, versus 15% for all of last year. […]
EvaluatePharma predicts some shuffling of the list of the world’s top drug firms through 2016. The top spot, which Pfizer has held for nine years, will be usurped by Sanofi next year. Sanofi’s projected five-year compound annual growth rate (CAGR) of 4% should allow it to maintain first place through 2016. Novartis is expected to […]
This month, the FDA launched a DNA-barcode library for 250 fish species, which can be accessed by outside labs and the public. The library is the result of a collaboration with the Smithsonian Institution to standardize testing methods using DNA sequencing in order to combat seafood fraud. Popular seafood such as red snapper, wild salmon […]
Among the 1,000 global public companies that invested the most in R&D in fiscal 2010, R&D spending reached $550 billion. The amount is a 9.3% increase from fiscal 2009 and a 5.6% increase from fiscal 2008. Revenues for the top 1,000 companies grew 15% in FY10. The fastest growth rate in R&D spending belonged to […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.

